Printer Friendly

CANTAB, BAXTER EXPAND COLLABORATION ON LM-CD45 ANTIBODY TO PREVENT ORGAN TRANSPLANT REJECTION

 CAMBRIDGE, England, July 12 /PRNewswire/ -- Cantab Pharmaceuticals plc (NASDAQ: CNTBY) and Baxter Healthcare Corporation announced today that they have agreed to expand their collaboration on the development and marketing of LM-CD45, a drug that is being tested as a way to prevent acute-rejection episodes following organ transplantation.
 Under the new agreement, Baxter receives exclusive worldwide manufacturing rights for LM-CD45 and exclusive rights to market the product in Japan and in Pacific Rim nations. Baxter also maintains its existing exclusive rights under a 1991 agreement to market LM-CD45 in North America and Europe. In return, Baxter will pay Cantab a licensing fee, royalties on future sales and payments based on achieving research milestones. The companies have collaborated on anti-CD45 since 1991.
 In April 1993, the companies presented favorable results of a phase I/II clinical trial of the drug. The study involved patients in the United Kingdom that were undergoing kidney transplants. The companies expect to begin expanded clinical trials in the United Kingdom later this year.
 "Since the commencement of our collaboration two years ago we have been impressed by the potential for Baxter to apply its considerable manufacturing resources to accelerate the development of LM-CD45," said Paul Haycock, M.D., president and chief executive officer of Cantab. "In addition, our evaluation of the future opportunity of LM-CD45 in Japan and the Far East has shown that Baxter is very well placed to carry out clinical development and marketing of the drug there, as well as in North America and Europe."
 Every year, more than 20,000 people around the world undergo kidney transplants and more then half of these patients suffer episodes of acute rejection. While current practice for treating acute rejection of transplanted organs uses drugs given to the patient to suppress the immune system after transplantation, LM-CD45 is used to prevent rejection by treating the donor organs before they are transplanted. Scientists believe that acute rejection episodes are caused in part by the kidney's dendritic cells, which carry a protein known as the CD45 antigen. Researchers at Cantab, in collaboration with Cambridge University, have developed a pair of monoclonal antibodies that bind to the CD45 antigen and are designed to destroy the dendritic cells: the drug is used ex vivo (outside the body) to pre-treat the donor organ before transplantation.
 "We are encouraged by the initial results of our clinical trial," said Donald W. Joseph, president of Baxter's renal division. "The expansion of our agreement with Cantab strengthens our commitment to global innovation and leadership in the field of kidney disease."
 "Baxter has extensive experience in manufacturing this type of product," said Dr. Haycock, Baxter has developed a process for producing LM-CD45 at its biotech group facilities in California. The company also has strong relationships with nephrologists in Japan and the Far East through its innovation in developing and marketing peritoneal dialysis products and services. As the worldwide leader in kidney dialysis products and services, Baxter is well positioned to bring new products to the transplant community. The company announced in May that it plans to introduce a line of tissue-typing diagnostic products for transplant physicians.
 Cantab is engaged in the research and development of biopharmaceuticals that use the highly selective properties of the immune system to treat disease. It is developing Leucocyte Modulators, which regulate or block immune system function, and Therapeutic Antigens, which activate specific immune responses. In addition to LM- CD45, Cantab has programs in the treatment of cervical cancer, the prevention of recurrence of genital herpes, the treatment of genital warts and research into the management of Crohn's disease. The company has established unique collaborations with researchers at the universities of Cambridge and Oxford.
 Baxter Healthcare Corporation is the principal domestic operating subsidiary of Deerfield, Ill.-based Baxter International Inc. Through its subsidiaries, Baxter is the leading manufacturer and marketer of healthcare products, systems and services worldwide. The company offers 120,000 products to healthcare providers in 100 countries.
 -0- 7/12/93
 /CONTACT: Paul Haycock, Ph.D., president and CEO of Cantab Pharmaceuticals plc, in the United Kingdom, 011-44-223-423413; or Geoffrey D. Fenton, corporate communications of Baxter Healthcare, 708-948-3436; or Andrew Waterworth of Ludgate Communications, in the United Kingdom, 011-44-71-253-2252; or Anthony Russo of Noonan/Russo Communications, 212-979-9180, for Cantab/
 (CNTBY)


CO: Cantab Pharmaceuticals plc; Baxter Healthcare Corporation ST: IN: MTC SU:

PS-LR -- NY017 -- 0314 07/12/93 10:08 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 12, 1993
Words:729
Previous Article:DIGITAL AND CUSTOMS TEAM UP; PARTNERSHIP REDEFINES IMPORTING PROCESS
Next Article:D.R. HORTON, INC. REPORTS SECOND QUARTER NEW SALES ORDERS INCREASE OF 94 PERCENT AND BACKLOG INCREASE OF 79 PERCENT
Topics:


Related Articles
CANTAB PHARMACEUTICALS REPORTS SECOND HALF YEAR AND YEAR END RESULTS
BAXTER, CANTAB SUCCESSFULLY COMPLETE PHASE I/II TRIALS FOR DRUG THAT REDUCES REJECTION IN ORGAN TRANSPLANTS
RESULTS OF PHASE I/II TRIAL ON LM-CD45 REPORTED AT BRITISH TRANSPLANT SOCIETY MEETING
CANTAB PHARMACEUTICALS SIGNS AGREEMENT WITH OXFORD UNIVERSITY AND REPORTS ON COLLABORATION WITH UNIVERSITY COLLEGE LONDON
BAXTER, CANTAB EXPAND COLLABORATION ON ANTI-CD45 ANTIBODY TO PREVENT ORGAN-TRANSPLANT REJECTION
CANTAB REPORTS THE START OF A CLINICAL TRIAL CONDUCTED BY THE UNIVERSITY OF WALES COLLEGE OF MEDICINE FOR CERVICAL CANCER
CANTAB PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END RESULTS
CANTAB EXPANDS INFLAMMATORY DISEASE PROGRAM THROUGH STANFORD UNIVERSITY COLLABORATION
CANTAB PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
CANTAB PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters